Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HANK cell therapy
- Development stage
- Unknown
- Lead developer
- Tianjin Second People's Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HANK (Highly Activated Natural Killer) cell therapy is an adoptive immunotherapy involving the ex vivo expansion and activation of natural killer (NK) cells. These cells are typically isolated from the peripheral blood of a patient (autologous) or a healthy donor (allogeneic). Through a standardized cultivation process, the NK cells are stimulated to reach a state of high cytotoxicity, characterized by increased expression of effector molecules like Perforin and Granzyme, and the Fc gamma receptor IIIa (CD16), which facilitates antibody-dependent cellular cytotoxicity (ADCC). Investigated primarily in China, specifically by Tianjin Second People's Hospital, this therapy is being evaluated for its ability to restore immune function in AIDS patients with poor immune reconstitution and to target solid tumors such as lung cancer. It aims to enhance the body's innate immune response against virally infected or malignant cells.
- Other names
- Highly Activated Natural Killer cell therapyHighly Activated NK CellshaNK cell therapy
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on HANK cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HANK cell therapy.